替拉韦:寻找丙型肝炎病毒感染的持续病毒学反应。

IF 1.8 4区医学 Q2 Medicine

Drugs of today Pub Date : 2011-11-01 DOI:10.1358/dot.2011.47.11.1678339

V Nehra, S A Rizza, R Talwani, Z Temesgen

{"title":"替拉韦:寻找丙型肝炎病毒感染的持续病毒学反应。","authors":"V Nehra, S A Rizza, R Talwani, Z Temesgen","doi":"10.1358/dot.2011.47.11.1678339","DOIUrl":null,"url":null,"abstract":"Telaprevir, a hepatitis C virus (HCV) NS3/NS4A protease inhibitor, was recently approved by the U.S. Food and Drug Administration for the treatment of chronic HCV genotype 1 infection. When given in combination with pegylated interferon and ribavirin, it demonstrated improved efficacy over conventional pegylated interferon and ribavirin therapy. Improvement in efficacy was also noted in African American patients who traditionally respond less well to conventional anti-HCV treatment. While the role of telaprevir in the management of chronic HCV infection remains to be fully defined, its development and licensure represents an important milestone in anti-HCV therapeutics.","PeriodicalId":11397,"journal":{"name":"Drugs of today","volume":" ","pages":"829-37"},"PeriodicalIF":1.8000,"publicationDate":"2011-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Telaprevir: looking for a sustained virologic response in hepatitis C virus infection.\",\"authors\":\"V Nehra, S A Rizza, R Talwani, Z Temesgen\",\"doi\":\"10.1358/dot.2011.47.11.1678339\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Telaprevir, a hepatitis C virus (HCV) NS3/NS4A protease inhibitor, was recently approved by the U.S. Food and Drug Administration for the treatment of chronic HCV genotype 1 infection. When given in combination with pegylated interferon and ribavirin, it demonstrated improved efficacy over conventional pegylated interferon and ribavirin therapy. Improvement in efficacy was also noted in African American patients who traditionally respond less well to conventional anti-HCV treatment. While the role of telaprevir in the management of chronic HCV infection remains to be fully defined, its development and licensure represents an important milestone in anti-HCV therapeutics.\",\"PeriodicalId\":11397,\"journal\":{\"name\":\"Drugs of today\",\"volume\":\" \",\"pages\":\"829-37\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2011-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs of today\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1358/dot.2011.47.11.1678339\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs of today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1358/dot.2011.47.11.1678339","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

Telaprevir是一种丙型肝炎病毒(HCV) NS3/NS4A蛋白酶抑制剂，最近被美国食品和药物管理局批准用于治疗慢性HCV基因型1感染。当与聚乙二醇化干扰素和利巴韦林联合使用时，它比传统的聚乙二醇化干扰素和利巴韦林治疗效果更好。非裔美国患者的疗效也有所改善，这些患者传统上对常规抗hcv治疗反应较差。尽管telaprevir在慢性HCV感染治疗中的作用尚未完全确定，但它的开发和许可代表了抗HCV治疗的一个重要里程碑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Telaprevir: looking for a sustained virologic response in hepatitis C virus infection.

Telaprevir, a hepatitis C virus (HCV) NS3/NS4A protease inhibitor, was recently approved by the U.S. Food and Drug Administration for the treatment of chronic HCV genotype 1 infection. When given in combination with pegylated interferon and ribavirin, it demonstrated improved efficacy over conventional pegylated interferon and ribavirin therapy. Improvement in efficacy was also noted in African American patients who traditionally respond less well to conventional anti-HCV treatment. While the role of telaprevir in the management of chronic HCV infection remains to be fully defined, its development and licensure represents an important milestone in anti-HCV therapeutics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drugs of today 医学-药学

CiteScore

3.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： An international, peer-reviewed journal publishing monographs on new products entering the market and review articles. Since its inception in 1965, Drugs of Today has established a reputation for excellence in providing physicians and other key healthcare professionals with practical, up-to-date monographs on recently approved and launched drugs.